Perspectives on the 2018 HHS Drug Pricing Guidance

This is the agenda for the Brazda Breakfast: Reporting on the Future of Health Care titled "Perspectives on 2018 HHS Drug Pricing Guidance" held on May 15, 2018, in Washington D.C.

9:00 a.m. – 9:05 a.m. Welcome and Introductions

William Pierce, MPIA, senior director, APCO Worldwide
Mary Ella Payne, R.N., MSPH, acting president and chief executive officer, Alliance for Health Policy

9:05 a.m. – 9:35 a.m. Perspectives from the Administration

Scott Gottlieb, M.D., Commissioner of Food and Drugs, U.S. Food and Drug Administration

9:40 a.m. – 10:30 a.m. Perspectives from Stakeholders

Lauren Aronson, executive director, Campaign for Sustainable Drug Pricing
Kristin Bass, MBA, senior vice president, Policy and Federal Affairs, Pharmaceutical Care Management Association
Justine Handelman, senior vice president, Office of Policy and Representation, Blue Cross Blue Shield Association
Lori Reilly, J.D., executive vice president, Policy, Research, and Membership, Pharmaceutical Research and Manufacturers of America

Jun24

past webinar

COVID-19 Webinar Series Session 20 - Tensions, Tradeoffs, and Takeaways: What’s at Stake for America 100 Days into the Pandemic  and Where We Go From Here

Just over 100 days have passed since the COVID-19 pandemic was declared a national emergency on March 13, 2020. The pandemic has led to sweeping ramifications throughout the American economy and society as a whole. During this interactive discussion, three preeminent health policy leaders examined the lessons learned three months into the crisis and lay out considerations for decision-makers as they work to stem the tide of the pandemic and build a more resilient health care system.

Learn More

Share